Glaucoma medications.

Abstract

Glaucoma is a common eye condition that affects millions of individuals worldwide, making it the second-leading cause of blindness. Because glaucoma is associated with increased IOP level, the primary goal in treatment of glaucoma includes lowering IOP to prevent further progression of the disease. While various surgical interventions exist, medical therapy is currently the first line of treatment. Medical treatment of glaucoma includes topical beta-blockers, alpha-2 agonists, prostaglandins, parasympathomimetics and CAIs. Anti-glaucoma agents help reduce IOP by affecting the production of aqueous humor or increasing the outflow of aqueous through the trabecular or uveoscleral pathway. Choosing an appropriate medical regimen can be challenging and various factors such as efficacy, safety, cost and patient compliance must be considered. First-line treatment is often topical beta-blockers or prostaglandin analogs. However, beta-blocking agents can be associated with systemic side effects and need to be used cautiously in patients with serious concomitant cardiopulmonary disease. Alpha-2 agonists and parasympathomimetics are often considered second- or third-line treatment options but good adjunctive agents. Oral CAIs are often indicated for patients with elevated IOP in an acute setting or for patients resistant to other glaucoma medications and patients who are not good surgical candidates.

• Authors: Bora Chae, Tulay Cakiner-Egilmez, Manishi Desai
• Journal: Insight (American Society of Ophthalmic Registered Nurses) (Insight) Vol. 38 Issue 1 Pg. 5-9; quiz 10 ( 2013) ISSN: 1060-135X [Print] United States
• PMID: 23505792 (Publication Type: Journal Article, Review)

Chemical References

• Antihypertensive Agents
• Parasympathomimetics

Topics

• Antihypertensive Agents (therapeutic use)
• Blindness (etiology, prevention & control)
• Glaucoma (complications, drug therapy, physiopathology)
• Humans
• Intraocular Pressure
• Parasympathomimetics (therapeutic use)